Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Jeson Sangaralingham

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|June 25, 2025
C-Type Natriuretic Peptide: Protecting the AortaS Jeson Sangaralingham, John C Burnett
Circulation|December 21, 2018
Relaxing With C-Type Natriuretic Peptide, the Guanylyl Cyclase B Receptor, and PericytesS Jeson Sangaralingham, John C Burnett
Hypertension (Dallas, Tex. : 1979)|May 20, 2026
C-Type Natriuretic Peptide and Cardiovascular-Renal Protection in SepsisS Jeson Sangaralingham, John C Burnett
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 17, 2014
Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodelingRosita Zakeri, John C Burnett, S Jeson Sangaralingham
European Heart Journal|March 26, 2019
C-type natriuretic peptide: the heart's guardian angelS Jeson Sangaralingham, Yang Chen, John C Burnett
Molecular and Cellular Biochemistry|August 24, 2007
Estrogen delays the progression of salt-induced cardiac hypertrophy by influencing the renin-angiotensin system in heterozygous proANP gene-disrupted miceS Jeson Sangaralingham, M Yat Tse, Stephen C Pang
The Journal of Endocrinology|June 27, 2007
Estrogen protects against the development of salt-induced cardiac hypertrophy in heterozygous proANP gene-disrupted miceS Jeson Sangaralingham, M Yat Tse, Stephen C Pang
Current Heart Failure Reports|June 29, 2010
CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal diseasePaul M McKie, S Jeson Sangaralingham, John C Burnett
JACC. Heart Failure|September 13, 2015
Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic PeptidesTomoko Ichiki, Brenda K Huntley, S Jeson Sangaralingham, et al.
Cardiovascular Research|August 25, 2022
Natriuretic peptide pathways in heart failure: further therapeutic possibilitiesS Jeson Sangaralingham, Michaela Kuhn, Valentina Cannone, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Arteriosclerosis, Thrombosis, and Vascular Biology|June 25, 2025
C-Type Natriuretic Peptide: Protecting the AortaS Jeson Sangaralingham, John C Burnett
Circulation|December 21, 2018
Relaxing With C-Type Natriuretic Peptide, the Guanylyl Cyclase B Receptor, and PericytesS Jeson Sangaralingham, John C Burnett
Hypertension (Dallas, Tex. : 1979)|May 20, 2026
C-Type Natriuretic Peptide and Cardiovascular-Renal Protection in SepsisS Jeson Sangaralingham, John C Burnett
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 17, 2014
Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodelingRosita Zakeri, John C Burnett, S Jeson Sangaralingham
European Heart Journal|March 26, 2019
C-type natriuretic peptide: the heart's guardian angelS Jeson Sangaralingham, Yang Chen, John C Burnett
Molecular and Cellular Biochemistry|August 24, 2007
Estrogen delays the progression of salt-induced cardiac hypertrophy by influencing the renin-angiotensin system in heterozygous proANP gene-disrupted miceS Jeson Sangaralingham, M Yat Tse, Stephen C Pang
The Journal of Endocrinology|June 27, 2007
Estrogen protects against the development of salt-induced cardiac hypertrophy in heterozygous proANP gene-disrupted miceS Jeson Sangaralingham, M Yat Tse, Stephen C Pang
Current Heart Failure Reports|June 29, 2010
CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal diseasePaul M McKie, S Jeson Sangaralingham, John C Burnett
JACC. Heart Failure|September 13, 2015
Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic PeptidesTomoko Ichiki, Brenda K Huntley, S Jeson Sangaralingham, et al.
Cardiovascular Research|August 25, 2022
Natriuretic peptide pathways in heart failure: further therapeutic possibilitiesS Jeson Sangaralingham, Michaela Kuhn, Valentina Cannone, et al.
Pageof 6